“…Specifically, those receiving ketamine had lower mean estimated baseline OCD-VAS score at mid-infusion (by À 4.52 points, SE ¼ 1.23, po0.005), 230 min (by 3.84 points, SE ¼ 1.59, po0.05), and 7 days (by À 3.67 points, SE ¼ 1.36, po0.05) post infusion, each with large effect size (Cohen's d40.8), Abbreviations: A, Asian; AA, African American; C, Caucasian; EX/RP, cognitive behavior therapy with exposure and response prevention; F, female; H, Hispanic; HDRS, Hamilton Depression Rating Scale; M, male; MDD, major depressive disorder; OCD, obsessive-compulsive disorder; SAD, social anxiety disorder; SP, specific phobia; SRI, serotonin reuptake inhibitor; Y-BOCS, Yale-Brown Obsessive-Compulsive Scale. Symptom dimensions were based on a five-factor model (Pinto et al, 2008;Schooler et al, 2008) and listed in order of clinical severity for each subject: Cln (contamination/cleaning); Dbt (doubt/checking); Hrd (hoarding); Sym (symmetry/ordering); Tab (taboo thoughts (aggressive, sexual, and religious obsessions)). Y-BOCS was rated at baseline before infusion (pre) and 1-week post-infusion (post).…”